

Table of Contents

Number	Title
1	Table 00: Comments
2	Table 01: Study population and enrolment information
3	Table 02: Patients by region, country, and cohort
4	Table 03 : Demographic Characteristics
5	Table 04 : Care setting , Type of AF and Insurance
6	Table 05 : Vital signs and life style
7	Table 06 : Clinical History
8	Table 07 : Treatment for stroke prophylaxis
9	Table 08: Treatment
10	Table 09 : Risk scores
11	Table 10: Treatment at baseline by CHA2DS2-VASc score
12	Table 11: Treatment at baseline by HAS-BLED score
13	Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
14	Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
15	Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
16	Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
17	Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
18	Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
19	Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4

Table 00: Comments

- 1 The data was extracted from the GARFIELD-AF registry database on 28 JUL 2016
- 2 The data includes retrospective patients in cohort 1 and prospective patients in cohort 1, 2, 3, 4 and 5
- 3 The variable 'Congestive heart failure' was split into 'History of CHF' and 'Current CHF' in cohorts 3, 4 and 5. History of and/or current CHF were used to identify CHF in cohort 3, 4 and 5 patients (Table 6)
- 4 The variable 'Coronary artery disease' was split into 'History of CAD' and 'Current CAD' in cohorts 3, 4 and 5. History of and/or current CAD were used to identify CAD in cohort 3, 4 and 5 patients (Table 6)
- 5 The variable 'Other thromboembolism' is not recorded for patients in cohort 3, 4 and 5
- 6 The option 'None' was added in the CRF for the 'Chronic renal disease' field in cohort 3, 4 and 5. The percentages for the variable 'Moderate to severe CKD' are estimated assuming that patients with 'unknown' stage of CKD are without 'Moderate to severe CKD' (Table 6)
- 7 Table 7 describes the baseline treatment for stroke prophylaxis. For each treatment group identifier options are mutually exclusive. The option 'unknown' includes combination of treatments
- 8 Table 8 shows the baseline treatment for stroke prophylaxis with non mutually exclusive groups
- 9 Table 12 shows INR values and TTR for patients treated with VKA±AP at baseline. INR readings during the first year of follow-up were included in the analysis. Values less than 0.8 or greater than 20 were removed since these values may not be plausible. Patients on VKA±AP at enrolment but with fewer than three readings during the follow-up were excluded from the analysis. Patient-level TTR was estimated by linear interpolation according to Rosendaal et al (1993), using 2.0-3.0 as the target INR range. TTR was estimated using INR readings until discontinuation or interruption of VKA or the end of follow-up. In addition, TTR was estimated between two consecutive INR readings only if the interval did not exceed 90 days.
- 10 Tables 13 and 14 describe events during the first year of follow-up for patients in cohorts 1-4. Only the first occurrence of each event was taken into account.
- 11 Table 13 Congestive heart failure during the follow-up includes new congestive heart failure or worsening of pre-existing congestive heart failure.

Table 01: Study population and enrolment information
Full Analysis Dataset : CZECH REPUBLIC

Number of prospective patients (C1+C2+C3+C4+C5)	1843
Number of enrolling sites	25
Number of enrolling countries	1
Enrolment period	16MAY2012 - 27JUL2016
Duration of enrolment (months)	50.4

Table 02: Patients by region, country, and cohort
Full Analysis Dataset : CZECH REPUBLIC

Region	Country	Cohort 2 (N=521)	Cohort 3 (N=427)	Cohort 4 (N=403)	Cohort 5 (N=492)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Europe	Czech Republic	521	427	403	492	1843	1351

Table 03 : Demographic Characteristics
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Sex, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	Male	289 (55.5)	229 (53.6)	197 (48.9)	267 (54.3)	982 (53.3)	715 (52.9)
	Female	232 (44.5)	198 (46.4)	206 (51.1)	225 (45.7)	861 (46.7)	636 (47.1)
Age at Diagnosis (Years)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	Mean (SD)	69.3 (9.6)	69.4 (10.3)	70.8 (10.0)	69.7 (10.1)	69.8 (10.0)	69.8 (10.0)
	Median (IQR)	69.0 (64.0 to 76.0)	70.0 (63.0 to 77.0)	71.0 (64.0 to 77.0)	70.0 (64.0 to 78.0)	70.0 (64.0 to 77.0)	70.0 (64.0 to 77.0)
	Min to Max	28 to 91	33 to 91	35 to 94	38 to 95	28 to 95	28 to 94
Age Group, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	<65	138 (26.5)	124 (29.0)	102 (25.3)	126 (25.6)	490 (26.6)	364 (26.9)
	65-74	226 (43.4)	166 (38.9)	155 (38.5)	201 (40.9)	748 (40.6)	547 (40.5)
	>=75	157 (30.1)	137 (32.1)	146 (36.2)	165 (33.5)	605 (32.8)	440 (32.6)
Time since AF Diagnosis (Weeks)	n (missing)	339 (182)	242 (185)	256 (147)	241 (251)	1078 (765)	837 (514)
	Mean (SD)	1.87 (1.69)	1.94 (1.71)	1.71 (1.69)	1.88 (1.78)	1.85 (1.71)	1.84 (1.70)
	Median (IQR)	1.20 (0.50 to 2.80)	1.40 (0.50 to 3.00)	1.00 (0.40 to 2.70)	1.20 (0.40 to 3.20)	1.20 (0.40 to 3.00)	1.20 (0.40 to 2.80)
	Min to Max	0.1 to 6.0	0.1 to 6.0	0.1 to 5.8	0.1 to 5.8	0.1 to 6.0	0.1 to 6.0
Race, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	490 (0)	1841 (0)	1351 (0)
	Caucasian	521 (100.0)	425 (99.5)	402 (99.8)	489 (99.8)	1837 (99.8)	1348 (99.8)
	Hispanic/Latino	-	1 (0.2)	-	1 (0.2)	2 (0.1)	1 (0.1)
	Mixed/Other	-	1 (0.2)	1 (0.2)	-	2 (0.1)	2 (0.1)
	Unknown	-	-	-	2	2	-

Table 03 : Demographic Characteristics
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Region, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	Europe	521 (100.0)	427 (100.0)	403 (100.0)	492 (100.0)	1843 (100.0)	1351 (100.0)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Care Setting	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
Speciality at Diagnosis, n(%)							
	Internal Medicine	207 (39.7)	119 (27.9)	156 (38.7)	98 (19.9)	580 (31.5)	482 (35.7)
	Cardiology	287 (55.1)	290 (67.9)	239 (59.3)	374 (76.0)	1190 (64.6)	816 (60.4)
	Neurology	4 (0.8)	-	1 (0.2)	2 (0.4)	7 (0.4)	5 (0.4)
	Geriatrics	1 (0.2)	-	-	-	1 (0.1)	1 (0.1)
	Primary Care/General Practice	22 (4.2)	18 (4.2)	7 (1.7)	18 (3.7)	65 (3.5)	47 (3.5)
Care Setting	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
Location at Diagnosis, n(%)							
	Hospital	259 (49.7)	182 (42.6)	198 (49.1)	189 (38.4)	828 (44.9)	639 (47.3)
	Office	247 (47.4)	224 (52.5)	180 (44.7)	269 (54.7)	920 (49.9)	651 (48.2)
	Emergency room	15 (2.9)	21 (4.9)	25 (6.2)	34 (6.9)	95 (5.2)	61 (4.5)
Type of AF Diagnosed, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	Permanent	31 (6.0)	25 (5.9)	39 (9.7)	20 (4.1)	115 (6.2)	95 (7.0)
	Persistent	78 (15.0)	53 (12.4)	46 (11.4)	62 (12.6)	239 (13.0)	177 (13.1)
	Paroxysmal	104 (20.0)	111 (26.0)	100 (24.8)	115 (23.4)	430 (23.3)	315 (23.3)
	New	308 (59.1)	238 (55.7)	218 (54.1)	295 (60.0)	1059 (57.5)	764 (56.6)
Treatment Costs, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)

Table 04 : Care setting , Type of AF and Insurance
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Treatment Sector, n(%)	Public insurance	484 (92.9)	400 (93.7)	394 (97.8)	484 (98.4)	1762 (95.6)	1278 (94.6)
	Private (insurance)	28 (5.4)	11 (2.6)	2 (0.5)	2 (0.4)	43 (2.3)	41 (3.0)
	Combination	9 (1.7)	16 (3.7)	7 (1.7)	6 (1.2)	38 (2.1)	32 (2.4)
	n (missing)	520 (0)	427 (0)	402 (0)	491 (0)	1840 (0)	1349 (0)
	In the public sector	359 (69.0)	269 (63.0)	248 (61.7)	310 (63.1)	1186 (64.5)	876 (64.9)
	In the private sector	161 (31.0)	158 (37.0)	154 (38.3)	181 (36.9)	654 (35.5)	473 (35.1)
	Unknown	1	-	1	1	3	2

Table 05 : Vital signs and life style
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Height (cm)	n (missing)	458 (63)	312 (115)	294 (109)	398 (94)	1462 (381)	1064 (287)
	Mean (SD)	171.5 (9.5)	171.5 (9.8)	171.5 (9.5)	171.2 (9.4)	171.4 (9.5)	171.5 (9.6)
	Median (IQR)	171.5 (165.0 to 178.0)	171.0 (165.0 to 178.0)	172.0 (164.0 to 179.0)	171.0 (164.0 to 178.0)	172.0 (165.0 to 178.0)	172.0 (165.0 to 178.0)
	Min to Max	138 to 204	138 to 200	147 to 198	145 to 203	138 to 204	138 to 204
Weight (kg)	n (missing)	458 (63)	312 (115)	294 (109)	398 (94)	1462 (381)	1064 (287)
	Mean (SD)	87.5 (17.9)	86.5 (18.0)	86.9 (16.6)	87.6 (18.9)	87.2 (17.9)	87.0 (17.6)
	Median (IQR)	85.0 (74.0 to 98.0)	83.0 (75.0 to 97.0)	86.0 (75.0 to 96.0)	85.0 (75.0 to 97.0)	85.0 (75.0 to 97.0)	85.0 (75.0 to 97.5)
	Min to Max	47 to 162	36 to 146	25 to 150	36 to 171	25 to 171	25 to 162
BMI (kg/m ²)	n (missing)	458 (63)	312 (115)	294 (109)	398 (94)	1462 (381)	1064 (287)
	Mean (SD)	29.7 (5.3)	29.4 (5.5)	29.6 (5.4)	29.8 (5.6)	29.6 (5.4)	29.6 (5.3)
	Median (IQR)	29.0 (26.0 to 33.0)	28.0 (26.0 to 32.0)	29.0 (26.0 to 32.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 33.0)	29.0 (26.0 to 32.0)
	Min to Max	18 to 48	13 to 51	9 to 51	13 to 66	9 to 66	9 to 51
BMI Category, n(%)	n (missing)	458 (63)	312 (115)	294 (109)	398 (94)	1462 (381)	1064 (287)
	<19	1 (0.2)	2 (0.6)	4 (1.4)	1 (0.3)	8 (0.5)	7 (0.7)
	19-<25	69 (15.1)	63 (20.2)	40 (13.6)	72 (18.1)	244 (16.7)	172 (16.2)
	25-<30	199 (43.4)	128 (41.0)	128 (43.5)	154 (38.7)	609 (41.7)	455 (42.8)
	30-<40	166 (36.2)	103 (33.0)	109 (37.1)	157 (39.4)	535 (36.6)	378 (35.5)
	>=40	23 (5.0)	16 (5.1)	13 (4.4)	14 (3.5)	66 (4.5)	52 (4.9)
Pulse (bpm)	n (missing)	518 (3)	423 (4)	402 (1)	482 (10)	1825 (18)	1343 (8)
	Mean (SD)	90.3 (26.4)	90.5 (27.1)	91.9 (28.1)	89.5 (26.6)	90.5 (27.0)	90.8 (27.2)
	Median (IQR)	85.0 (70.0 to 110.0)	85.0 (70.0 to 107.0)	85.0 (72.0 to 108.0)	84.0 (70.0 to 105.0)	85.0 (70.0 to 107.0)	85.0 (70.0 to 108.0)
	Min to Max	42 to 200	40 to 203	40 to 250	36 to 200	36 to 250	40 to 250

Table 05 : Vital signs and life style
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Systolic BP (mm Hg)	n (missing)	516 (5)	422 (5)	401 (2)	472 (20)	1811 (32)	1339 (12)
	Mean (SD)	135.7 (18.9)	136.1 (20.7)	136.0 (17.0)	134.3 (16.5)	135.5 (18.3)	135.9 (18.9)
	Median (IQR)	130.0 (120.0 to 146.5)	135.0 (120.0 to 145.0)	135.0 (125.0 to 145.0)	130.0 (120.0 to 145.0)	135.0 (120.0 to 145.0)	135.0 (120.0 to 145.0)
	Min to Max	90 to 230	90 to 270	90 to 195	90 to 220	90 to 270	90 to 270
Diastolic BP (mm Hg)	n (missing)	516 (5)	422 (5)	401 (2)	472 (20)	1811 (32)	1339 (12)
	Mean (SD)	81.7 (11.0)	81.8 (11.7)	81.8 (11.1)	81.9 (11.3)	81.8 (11.3)	81.8 (11.3)
	Median (IQR)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)	80.0 (75.0 to 90.0)
	Min to Max	55 to 138	50 to 180	50 to 120	50 to 132	50 to 180	50 to 180
LVEF (%)	n (missing)	425 (96)	328 (99)	293 (110)	368 (124)	1414 (429)	1046 (305)
	Mean (SD)	56.3 (11.3)	57.6 (10.0)	57.9 (10.3)	56.7 (11.0)	57.0 (10.7)	57.2 (10.6)
	Median (IQR)	60.0 (54.0 to 64.0)	60.0 (55.0 to 65.0)	60.0 (55.0 to 65.0)	60.0 (54.0 to 63.5)	60.0 (55.0 to 65.0)	60.0 (55.0 to 65.0)
	Min to Max	13 to 77	17 to 79	20 to 82	15 to 78	13 to 82	13 to 82
LVEF Category, n (n(%))	n (missing)	425 (96)	328 (99)	293 (110)	368 (124)	1414 (429)	1046 (305)
	<40%	41 (9.6)	20 (6.1)	17 (5.8)	31 (8.4)	109 (7.7)	78 (7.5)
	>=40%	384 (90.4)	308 (93.9)	276 (94.2)	337 (91.6)	1305 (92.3)	968 (92.5)
History of Hypertension, n(%)	n (missing)	521 (0)	425 (0)	403 (0)	491 (0)	1840 (0)	1349 (0)
	No	65 (12.5)	46 (10.8)	47 (11.7)	72 (14.7)	230 (12.5)	158 (11.7)
	Yes	456 (87.5)	379 (89.2)	356 (88.3)	419 (85.3)	1610 (87.5)	1191 (88.3)

Table 05 : Vital signs and life style
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
	Unknown	-	2	-	1	3	2
Alcohol Consumption, n(%)	n (missing)	487 (0)	399 (0)	380 (0)	460 (0)	1726 (0)	1266 (0)
	Abstinent	211 (43.3)	167 (41.9)	196 (51.6)	202 (43.9)	776 (45.0)	574 (45.3)
	Light	244 (50.1)	198 (49.6)	162 (42.6)	226 (49.1)	830 (48.1)	604 (47.7)
	Moderate	31 (6.4)	34 (8.5)	20 (5.3)	29 (6.3)	114 (6.6)	85 (6.7)
	Heavy	1 (0.2)	-	2 (0.5)	3 (0.7)	6 (0.3)	3 (0.2)
	Unknown	34	28	23	32	117	85
Smoker, n(%)	n (missing)	493 (0)	405 (0)	387 (0)	479 (0)	1764 (0)	1285 (0)
	No	336 (68.2)	290 (71.6)	265 (68.5)	335 (69.9)	1226 (69.5)	891 (69.3)
	Ex-smoker	109 (22.1)	71 (17.5)	78 (20.2)	83 (17.3)	341 (19.3)	258 (20.1)
	Current smoker	48 (9.7)	44 (10.9)	44 (11.4)	61 (12.7)	197 (11.2)	136 (10.6)
	Unknown	28	22	16	13	79	66

Table 06 : Clinical History
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Congestive heart failure, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	433 (83.1)	381 (89.2)	370 (91.8)	428 (87.0)	1612 (87.5)	1184 (87.6)
	Yes	88 (16.9)	46 (10.8)	33 (8.2)	64 (13.0)	231 (12.5)	167 (12.4)
Congestive Heart Failure NYHA Class, n(%)	n (missing)	87 (433)	42 (381)	28 (370)	57 (428)	214 (1612)	157 (1184)
	I	8 (9.2)	3 (7.1)	-	1 (1.8)	12 (5.6)	11 (7.0)
	II	52 (59.8)	29 (69.0)	17 (60.7)	34 (59.6)	132 (61.7)	98 (62.4)
	III	22 (25.3)	10 (23.8)	11 (39.3)	20 (35.1)	63 (29.4)	43 (27.4)
	IV	5 (5.7)	-	-	2 (3.5)	7 (3.3)	5 (3.2)
	Unknown	1	4	5	7	17	10
Coronary artery disease, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	434 (83.3)	340 (79.6)	318 (78.9)	404 (82.1)	1496 (81.2)	1092 (80.8)
	Yes	87 (16.7)	87 (20.4)	85 (21.1)	88 (17.9)	347 (18.8)	259 (19.2)
Acute coronary syndrome, n(%)	n (missing)	521 (0)	426 (0)	400 (0)	490 (0)	1837 (0)	1347 (0)
	No	472 (90.6)	376 (88.3)	349 (87.3)	440 (89.8)	1637 (89.1)	1197 (88.9)
	Yes	49 (9.4)	50 (11.7)	51 (12.8)	50 (10.2)	200 (10.9)	150 (11.1)
	Unknown	-	1	3	2	6	4
Carotid Occlusive Disease, n(%)	n (missing)	521 (0)	423 (0)	395 (0)	478 (0)	1817 (0)	1339 (0)
	No	505 (96.9)	417 (98.6)	387 (98.0)	467 (97.7)	1776 (97.7)	1309 (97.8)

Table 06 : Clinical History
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
	Yes	16 (3.1)	6 (1.4)	8 (2.0)	11 (2.3)	41 (2.3)	30 (2.2)
	Unknown	-	4	8	14	26	12
PE or DVT, n(%)	n (missing)	521 (0)	427 (0)	401 (0)	490 (0)	1839 (0)	1349 (0)
	No	497 (95.4)	410 (96.0)	382 (95.3)	464 (94.7)	1753 (95.3)	1289 (95.6)
	Yes	24 (4.6)	17 (4.0)	19 (4.7)	26 (5.3)	86 (4.7)	60 (4.4)
	Unknown	-	-	2	2	4	2
Other Thromboemboli sm, n(%)	n (missing)	521 (0)	0 (427)	0 (403)	0 (492)	521 (1322)	521 (830)
	No	512 (98.3)	-	-	-	512 (98.3)	512 (98.3)
	Yes	9 (1.7)	-	-	-	9 (1.7)	9 (1.7)
Systemic Embolization, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	491 (0)	1842 (0)	1351 (0)
	No	519 (99.6)	422 (98.8)	398 (98.8)	484 (98.6)	1823 (99.0)	1339 (99.1)
	Yes	2 (0.4)	5 (1.2)	5 (1.2)	7 (1.4)	19 (1.0)	12 (0.9)
	Unknown	-	-	-	1	1	-
Coronary Artery Bypass Graft, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	491 (0)	1842 (0)	1351 (0)
	No	498 (95.6)	410 (96.0)	388 (96.3)	469 (95.5)	1765 (95.8)	1296 (95.9)
	Yes	23 (4.4)	17 (4.0)	15 (3.7)	22 (4.5)	77 (4.2)	55 (4.1)
	Unknown	-	-	-	1	1	-
Stroke/TIA, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)

Table 06 : Clinical History
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
	No	476 (91.4)	387 (90.6)	361 (89.6)	446 (90.7)	1670 (90.6)	1224 (90.6)
	Yes	45 (8.6)	40 (9.4)	42 (10.4)	46 (9.3)	173 (9.4)	127 (9.4)
Stroke, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	493 (94.6)	403 (94.4)	380 (94.3)	460 (93.5)	1736 (94.2)	1276 (94.4)
	Yes	28 (5.4)	24 (5.6)	23 (5.7)	32 (6.5)	107 (5.8)	75 (5.6)
History of Bleeding, n(%)	n (missing)	521 (0)	425 (0)	402 (0)	490 (0)	1838 (0)	1348 (0)
	No	513 (98.5)	415 (97.6)	395 (98.3)	482 (98.4)	1805 (98.2)	1323 (98.1)
	Yes	8 (1.5)	10 (2.4)	7 (1.7)	8 (1.6)	33 (1.8)	25 (1.9)
	Unknown	-	2	1	2	5	3
Hypercholester olaemia, n(%)	n (missing)	521 (0)	400 (0)	373 (0)	457 (0)	1751 (0)	1294 (0)
	No	252 (48.4)	167 (41.8)	159 (42.6)	186 (40.7)	764 (43.6)	578 (44.7)
	Yes	269 (51.6)	233 (58.3)	214 (57.4)	271 (59.3)	987 (56.4)	716 (55.3)
	Unknown	-	27	30	35	92	57
Diabetes, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	357 (68.5)	312 (73.1)	286 (71.0)	353 (71.7)	1308 (71.0)	955 (70.7)
	Type I	3 (0.6)	2 (0.5)	4 (1.0)	6 (1.2)	15 (0.8)	9 (0.7)
	Type II	161 (30.9)	113 (26.5)	113 (28.0)	133 (27.0)	520 (28.2)	387 (28.6)
Diabetes, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	357 (68.5)	312 (73.1)	286 (71.0)	353 (71.7)	1308 (71.0)	955 (70.7)
	Yes	164 (31.5)	115 (26.9)	117 (29.0)	139 (28.3)	535 (29.0)	396 (29.3)
Cirrhosis, n(%)	n (missing)	521 (0)	411 (0)	395 (0)	467 (0)	1794 (0)	1327 (0)
	No	517 (99.2)	407 (99.0)	395 (100.0)	465 (99.6)	1784 (99.4)	1319 (99.4)
	Yes	4 (0.8)	4 (1.0)	-	2 (0.4)	10 (0.6)	8 (0.6)

Table 06 : Clinical History
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
	Unknown	-	16	8	25	49	24
Dementia, n(%)	n (missing)	521 (0)	426 (0)	402 (0)	490 (0)	1839 (0)	1349 (0)
	No	516 (99.0)	425 (99.8)	401 (99.8)	485 (99.0)	1827 (99.3)	1342 (99.5)
	Yes	5 (1.0)	1 (0.2)	1 (0.2)	5 (1.0)	12 (0.7)	7 (0.5)
	Unknown	-	1	1	2	4	2
Hyperthyroidism, n(%)	n (missing)	521 (0)	422 (0)	399 (0)	464 (0)	1806 (0)	1342 (0)
	No	517 (99.2)	419 (99.3)	396 (99.2)	457 (98.5)	1789 (99.1)	1332 (99.3)
	Yes	4 (0.8)	3 (0.7)	3 (0.8)	7 (1.5)	17 (0.9)	10 (0.7)
	Unknown	-	5	4	28	37	9
Hypothyroidism, n(%)	n (missing)	521 (0)	421 (0)	399 (0)	464 (0)	1805 (0)	1341 (0)
	No	473 (90.8)	367 (87.2)	359 (90.0)	418 (90.1)	1617 (89.6)	1199 (89.4)
	Yes	48 (9.2)	54 (12.8)	40 (10.0)	46 (9.9)	188 (10.4)	142 (10.6)
	Unknown	-	6	4	28	38	10
Vascular Disease, n(%)	n (missing)	521 (0)	427 (0)	400 (3)	491 (1)	1839 (4)	1348 (3)
	No	447 (85.8)	367 (85.9)	329 (82.3)	411 (83.7)	1554 (84.5)	1143 (84.8)
	Yes	74 (14.2)	60 (14.1)	71 (17.8)	80 (16.3)	285 (15.5)	205 (15.2)
Moderate to Severe CKD, n(%)	n (missing)	521 (0)	427 (0)	403 (0)	492 (0)	1843 (0)	1351 (0)
	No	498 (95.6)	415 (97.2)	393 (97.5)	479 (97.4)	1785 (96.9)	1306 (96.7)
	Yes	23 (4.4)	12 (2.8)	10 (2.5)	13 (2.6)	58 (3.1)	45 (3.3)

**Table 07 : Treatment for stroke prophylaxis
Full Analysis Dataset : CZECH REPUBLIC**

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Baseline Treatment, n(%)	n (missing)	516 (0)	425 (0)	396 (0)	487 (0)	1824 (0)	1337 (0)
	VKA	269 (52.1)	229 (53.9)	211 (53.3)	278 (57.1)	987 (54.1)	709 (53.0)
	VKA+AP	43 (8.3)	30 (7.1)	20 (5.1)	39 (8.0)	132 (7.2)	93 (7.0)
	FXA	27 (5.2)	45 (10.6)	41 (10.4)	44 (9.0)	157 (8.6)	113 (8.5)
	FXA+AP	4 (0.8)	5 (1.2)	4 (1.0)	8 (1.6)	21 (1.2)	13 (1.0)
	DTI	14 (2.7)	12 (2.8)	15 (3.8)	18 (3.7)	59 (3.2)	41 (3.1)
	DTI+AP	3 (0.6)	-	3 (0.8)	2 (0.4)	8 (0.4)	6 (0.4)
	AP	98 (19.0)	48 (11.3)	55 (13.9)	59 (12.1)	260 (14.3)	201 (15.0)
	NONE	58 (11.2)	56 (13.2)	47 (11.9)	39 (8.0)	200 (11.0)	161 (12.0)
	Unknown	5	2	7	5	19	14
	VKA±AP	312 (60.5)	259 (60.9)	231 (58.3)	317 (65.1)	1119 (61.3)	802 (60.0)
	FXA±AP	31 (6.0)	50 (11.8)	45 (11.4)	52 (10.7)	178 (9.8)	126 (9.4)
	DTI±AP	17 (3.3)	12 (2.8)	18 (4.5)	20 (4.1)	67 (3.7)	47 (3.5)
	FXA/DTI	41 (7.9)	57 (13.4)	56 (14.1)	62 (12.7)	216 (11.8)	154 (11.5)
	FXA/DTI+AP	7 (1.4)	5 (1.2)	7 (1.8)	10 (2.1)	29 (1.6)	19 (1.4)
	FXA/DTI±AP	48 (9.3)	62 (14.6)	63 (15.9)	72 (14.8)	245 (13.4)	173 (12.9)
	AC	310 (60.1)	286 (67.3)	267 (67.4)	340 (69.8)	1203 (66.0)	863 (64.5)
	AC+AP	50 (9.7)	35 (8.2)	27 (6.8)	49 (10.1)	161 (8.8)	112 (8.4)
	AC±AP	360 (69.8)	321 (75.5)	294 (74.2)	389 (79.9)	1364 (74.8)	975 (72.9)

Table 08: Treatment
Full Analysis Dataset : CZECH REPUBLIC

	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
Anti-platelet (non mutually exclusive groups)						
Glycoprotein inhibitors	2 (0.4)	-	-		2 (0.1)	2 (0.1)
ADP receptor/P2Y12 inhibitors	15 (2.9)	10 (2.3)	8 (2.0)	19 (3.9)	52 (2.8)	33 (2.4)
Prostaglandin Cox inhibitors	1 (0.2)	-	-		1 (0.1)	1 (0.1)
ASA	-	7 (1.6)	-	11 (2.2)	18 (1.0)	7 (0.5)
	130 (25.0)	69 (16.2)	80 (19.9)	92 (18.7)	371 (20.1)	279 (20.7)
Anticoagulant drugs (non mutually exclusive groups)						
VKA	316 (60.7)	261 (61.1)	237 (58.8)	321 (65.2)	1135 (61.6)	814 (60.3)
FXa	34 (6.5)	52 (12.2)	50 (12.4)	57 (11.6)	193 (10.5)	136 (10.1)
DTI	18 (3.5)	13 (3.0)	19 (4.7)	21 (4.3)	71 (3.9)	50 (3.7)
Heparinoid	1 (0.2)	-	-		1 (0.1)	1 (0.1)
Heparins	72 (13.8)	53 (12.4)	40 (9.9)	36 (7.3)	201 (10.9)	165 (12.2)
Other	3 (0.6)	-	-	2 (0.4)	5 (0.3)	3 (0.2)

Table 09 : Risk scores
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
CHADS2 Score	n (missing)	521 (0)	425 (2)	403 (0)	489 (3)	1838 (5)	1349 (2)
	Mean (SD)	1.9 (1.1)	1.8 (1.0)	1.9 (1.1)	1.8 (1.1)	1.8 (1.1)	1.9 (1.1)
	Median (IQR)	2.0 (1.0 to 3.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)	2.0 (1.0 to 2.0)
	Min to Max	0 to 5	0 to 6	0 to 5	0 to 6	0 to 6	0 to 6
CHADS2 score categories, n(%)	n (missing)	521 (0)	425 (2)	403 (0)	489 (3)	1838 (5)	1349 (2)
	0	20 (3.8)	15 (3.5)	26 (6.5)	37 (7.6)	98 (5.3)	61 (4.5)
	1	211 (40.5)	173 (40.7)	144 (35.7)	168 (34.4)	696 (37.9)	528 (39.1)
	2	156 (29.9)	152 (35.8)	148 (36.7)	172 (35.2)	628 (34.2)	456 (33.8)
	3	91 (17.5)	60 (14.1)	46 (11.4)	79 (16.2)	276 (15.0)	197 (14.6)
	4	31 (6.0)	15 (3.5)	25 (6.2)	25 (5.1)	96 (5.2)	71 (5.3)
	5	12 (2.3)	9 (2.1)	14 (3.5)	6 (1.2)	41 (2.2)	35 (2.6)
	6	-	1 (0.2)	-	2 (0.4)	3 (0.2)	1 (0.1)
CHA2DS2- VASc Score	n (missing)	521 (0)	425 (2)	400 (3)	487 (5)	1833 (10)	1346 (5)
	Mean (SD)	3.3 (1.5)	3.1 (1.5)	3.3 (1.6)	3.2 (1.6)	3.2 (1.5)	3.2 (1.5)
	Median (IQR)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)	3.0 (2.0 to 4.0)
	Min to Max	0 to 8	0 to 8	0 to 8	0 to 9	0 to 9	0 to 8
CHA2DS2- VASc score categories, n(%)	n (missing)	521 (0)	425 (2)	400 (3)	487 (5)	1833 (10)	1346 (5)
	0	5 (1.0)	7 (1.6)	6 (1.5)	10 (2.1)	28 (1.5)	18 (1.3)
	1	48 (9.2)	41 (9.6)	42 (10.5)	61 (12.5)	192 (10.5)	131 (9.7)
	2	122 (23.4)	104 (24.5)	81 (20.3)	92 (18.9)	399 (21.8)	307 (22.8)
	3	143 (27.4)	110 (25.9)	93 (23.3)	115 (23.6)	461 (25.2)	346 (25.7)
	4	108 (20.7)	95 (22.4)	95 (23.8)	115 (23.6)	413 (22.5)	298 (22.1)

Table 09 : Risk scores
Full Analysis Dataset : CZECH REPUBLIC

Variable	Statistics	Cohort 2 (N=521) (n %)	Cohort 3 (N=427) (n %)	Cohort 4 (N=403) (n %)	Cohort 5 (N=492) (n %)	Total Prospective patients Cohorts 1 to 5 (N=1843)	Total Prospective patients Cohorts 1 to 4 (N=1351)
	5	51 (9.8)	41 (9.6)	48 (12.0)	64 (13.1)	204 (11.1)	140 (10.4)
	6-9	44 (8.4)	27 (6.4)	35 (8.8)	30 (6.2)	136 (7.4)	106 (7.9)
HAS-BLED score	n (missing)	376 (145)	383 (44)	372 (31)	420 (72)	1551 (292)	1131 (220)
	Mean (SD)	1.3 (0.9)	1.3 (0.9)	1.2 (0.8)	1.1 (0.8)	1.2 (0.8)	1.3 (0.8)
	Median (IQR)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)
	Min to Max	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4	0 to 4
HAS-BLED score categories, n(%)	n (missing)	376 (145)	383 (44)	372 (31)	420 (72)	1551 (292)	1131 (220)
	0	56 (14.9)	65 (17.0)	60 (16.1)	81 (19.3)	262 (16.9)	181 (16.0)
	1	173 (46.0)	176 (46.0)	207 (55.6)	213 (50.7)	769 (49.6)	556 (49.2)
	2	114 (30.3)	108 (28.2)	82 (22.0)	111 (26.4)	415 (26.8)	304 (26.9)
	3	30 (8.0)	32 (8.4)	22 (5.9)	13 (3.1)	97 (6.3)	84 (7.4)
	4	3 (0.8)	2 (0.5)	1 (0.3)	2 (0.5)	8 (0.5)	6 (0.5)

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : CZECH REPUBLIC

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	
Cohort 2	0	3	60	-	-	-	-	-	-	1	20	-	-	-	-	1	20	-
	1	22	45.8	1	2.1	4	8.3	-	-	1	2.1	-	-	8	16.7	12	25	-
	2	65	53.7	3	2.5	7	5.8	-	-	2	1.7	-	-	29	24	15	12.4	1
	3	76	53.5	11	7.7	7	4.9	3	2.1	2	1.4	1	0.7	26	18.3	16	11.3	1
	4	58	54.7	15	14.2	5	4.7	1	0.9	4	3.8	1	0.9	17	16	5	4.7	2
	5	30	60	3	6	3	6	-	-	1	2	-	-	10	20	3	6	1
	6-9	15	34.1	10	22.7	1	2.3	-	-	3	6.8	1	2.3	8	18.2	6	13.6	-
Cohort 3	0	2	28.6	-	-	1	14.3	-	-	1	14.3	-	-	1	14.3	2	28.6	-
	1	20	48.8	1	2.4	3	7.3	-	-	2	4.9	-	-	7	17.1	8	19.5	-
	2	60	58.3	5	4.9	6	5.8	-	-	2	1.9	-	-	12	11.7	18	17.5	1
	3	62	56.4	8	7.3	11	10	2	1.8	5	4.5	-	-	8	7.3	14	12.7	-
	4	56	58.9	8	8.4	15	15.8	-	-	2	2.1	-	-	9	9.5	5	5.3	-
	5	20	50	4	10	4	10	-	-	-	-	-	-	5	12.5	7	17.5	1
	6-9	9	33.3	3	11.1	5	18.5	3	11.1	-	-	-	-	5	18.5	2	7.4	-
Cohort 4	0	2	33.3	-	-	2	33.3	-	-	-	-	-	-	1	16.7	1	16.7	-
	1	15	36.6	-	-	7	17.1	-	-	2	4.9	-	-	8	19.5	9	22	1
	2	50	63.3	2	2.5	9	11.4	-	-	2	2.5	-	-	9	11.4	7	8.9	2
	3	53	58.9	6	6.7	9	10	1	1.1	1	1.1	-	-	8	8.9	12	13.3	3
	4	52	55.3	5	5.3	8	8.5	2	2.1	3	3.2	1	1.1	11	11.7	12	12.8	1
	5	24	50	4	8.3	6	12.5	-	-	3	6.3	1	2.1	6	12.5	4	8.3	-
	6-9	15	42.9	3	8.6	-	-	1	2.9	3	8.6	1	2.9	10	28.6	2	5.7	-
Cohort 5	0	1	10	-	-	3	30	-	-	1	10	-	-	2	20	3	30	-
	1	24	39.3	2	3.3	8	13.1	2	3.3	5	8.2	-	-	6	9.8	14	23	-
	2	54	60	5	5.6	13	14.4	-	-	4	4.4	-	-	8	8.9	6	6.7	2
	3	76	66.7	9	7.9	8	7	3	2.6	2	1.8	1	0.9	11	9.6	4	3.5	1
	4	78	69	8	7.1	5	4.4	-	-	2	1.8	1	0.9	13	11.5	6	5.3	2
	5	31	48.4	10	15.6	4	6.3	2	3.1	2	3.1	-	-	13	20.3	2	3.1	-
	6-9	12	40	5	16.7	3	10	1	3.3	2	6.7	-	-	4	13.3	3	10	-

Table 10: Treatment at baseline by CHA2DS2-VASc score
Full Analysis Dataset : CZECH REPUBLIC

Cohort	CHA2DS2-VASc	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 5	0	8	28.6	-	-	6	21.4	-	-	3	10.7	-	-	4	14.3	7	25	-
	1	81	42.4	4	2.1	22	11.5	2	1	10	5.2	-	-	29	15.2	43	22.5	1
	2	229	58.3	15	3.8	35	8.9	-	-	10	2.5	-	-	58	14.8	46	11.7	6
	3	267	58.6	34	7.5	35	7.7	9	2	10	2.2	2	0.4	53	11.6	46	10.1	5
	4	244	59.8	36	8.8	33	8.1	3	0.7	11	2.7	3	0.7	50	12.3	28	6.9	5
	5	105	52	21	10.4	17	8.4	2	1	6	3	1	0.5	34	16.8	16	7.9	2
	6-9	51	37.5	21	15.4	9	6.6	5	3.7	8	5.9	2	1.5	27	19.9	13	9.6	-
Total Prospective patients Cohorts 1 to 4	0	7	38.9	-	-	3	16.7	-	-	2	11.1	-	-	2	11.1	4	22.2	-
	1	57	43.8	2	1.5	14	10.8	-	-	5	3.8	-	-	23	17.7	29	22.3	1
	2	175	57.8	10	3.3	22	7.3	-	-	6	2	-	-	50	16.5	40	13.2	4
	3	191	55.8	25	7.3	27	7.9	6	1.8	8	2.3	1	0.3	42	12.3	42	12.3	4
	4	166	56.3	28	9.5	28	9.5	3	1	9	3.1	2	0.7	37	12.5	22	7.5	3
	5	74	53.6	11	8	13	9.4	-	-	4	2.9	1	0.7	21	15.2	14	10.1	2
	6-9	39	36.8	16	15.1	6	5.7	4	3.8	6	5.7	2	1.9	23	21.7	10	9.4	-

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : CZECH REPUBLIC

		VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
Cohort	HAS-BLED	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Cohort 2	0	29	52.7	-	-	6	10.9	-	-	3	5.5	-	-	-	-	17	30.9	1
	1	116	68.6	6	3.6	11	6.5	1	0.6	7	4.1	-	-	13	7.7	15	8.9	4
	2	40	35.1	25	21.9	2	1.8	2	1.8	3	2.6	2	1.8	39	34.2	1	0.9	-
	3	10	33.3	4	13.3	-	-	1	3.3	1	3.3	1	3.3	13	43.3	-	-	-
	4-9	1	33.3	1	33.3	-	-	-	-	-	-	-	-	1	33.3	-	-	-
Cohort 3	0	41	63.1	-	-	4	6.2	-	-	3	4.6	-	-	-	-	17	26.2	-
	1	110	62.9	4	2.3	20	11.4	-	-	6	3.4	-	-	16	9.1	19	10.9	1
	2	35	32.7	18	16.8	17	15.9	3	2.8	3	2.8	-	-	18	16.8	13	12.1	1
	3	11	34.4	6	18.8	2	6.3	2	6.3	-	-	-	-	7	21.9	4	12.5	-
	4-9	1	50	-	-	-	-	-	-	-	-	-	-	1	50	-	-	-
Cohort 4	0	35	60.3	-	-	8	13.8	-	-	2	3.4	-	-	-	-	13	22.4	2
	1	133	65.8	3	1.5	22	10.9	-	-	6	3	-	-	12	5.9	26	12.9	5
	2	21	25.6	9	11	9	11	3	3.7	6	7.3	3	3.7	27	32.9	4	4.9	-
	3	5	22.7	4	18.2	1	4.5	1	4.5	1	4.5	-	-	9	40.9	1	4.5	-
	4-9	1	100	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cohort 5	0	43	53.1	-	-	17	21	-	-	5	6.2	-	-	-	-	16	19.8	-
	1	155	73.8	3	1.4	22	10.5	1	0.5	9	4.3	-	-	7	3.3	13	6.2	3
	2	32	29.1	26	23.6	3	2.7	6	5.5	2	1.8	1	0.9	37	33.6	3	2.7	1
	3	4	30.8	3	23.1	-	-	-	-	-	-	-	-	6	46.2	-	-	-
	4-9	1	50	-	-	-	-	-	-	-	-	-	-	1	50	-	-	-
Total Prospective patients Cohorts 1 to 5	0	148	57.1	-	-	35	13.5	-	-	13	5	-	-	-	-	63	24.3	3
	1	514	68	16	2.1	75	9.9	2	0.3	28	3.7	-	-	48	6.3	73	9.7	13
	2	128	31	78	18.9	31	7.5	14	3.4	14	3.4	6	1.5	121	29.3	21	5.1	2
	3	30	30.9	17	17.5	3	3.1	4	4.1	2	2.1	1	1	35	36.1	5	5.2	-

Table 11: Treatment at baseline by HAS-BLED score
Full Analysis Dataset : CZECH REPUBLIC

Cohort	HAS-BLED	VKA		VKA+AP		FXA		FXA+AP		DTI		DTI+AP		AP		NONE		UNKNOWN
		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n
Total Prospective patients Cohorts 1 to 4	4-9	4	50	1	12.5	-	-	-	-	-	-	-	-	3	37.5	-	-	-
	0	105	59	-	-	18	10.1	-	-	8	4.5	-	-	-	-	47	26.4	3
	1	359	65.8	13	2.4	53	9.7	1	0.2	19	3.5	-	-	41	7.5	60	11	10
	2	96	31.7	52	17.2	28	9.2	8	2.6	12	4	5	1.7	84	27.7	18	5.9	1
	3	26	31	14	16.7	3	3.6	4	4.8	2	2.4	1	1.2	29	34.5	5	6	-
	4-9	3	50	1	16.7	-	-	-	-	-	-	-	-	2	33.3	-	-	-

**Table 12: INR values and time in therapeutic range (TTR) during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC**

Variable	Statistics	Cohort 2 (N=312) (n %)	Cohort 3 (N=259) (n %)	Cohort 4 (N=231) (n %)	Total Prospective patients Cohorts 1 to 4 (N=802)
TTR value, n(%)	n (missing)	174 (138)	153 (106)	108 (123)	435 (367)
	<65	97 (55.7)	86 (56.2)	61 (56.5)	244 (56.1)
	>=65	77 (44.3)	67 (43.8)	47 (43.5)	191 (43.9)
TTR	n (missing)	174 (138)	153 (106)	108 (123)	435 (367)
	Mean (SD)	60.9 (26.4)	59.7 (25.5)	62.6 (25.2)	60.9 (25.7)
	Median (IQR)	62.2 (42.4 to 82.6)	63.2 (43.6 to 78.6)	62.0 (49.4 to 82.1)	62.2 (44.7 to 81.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0	0.0 to 100.0
INR value, n(%)	n	1635	1421	924	3980
	2-3	876 (53.6)	753 (53.0)	506 (54.8)	2135 (53.6)
	<2	472 (28.9)	425 (29.9)	254 (27.5)	1151 (28.9)
	>3	287 (17.6)	243 (17.1)	164 (17.7)	694 (17.4)
INR	n	1635	1421	924	3980
	Mean (SD)	2.4 (0.9)	2.4 (0.8)	2.4 (0.8)	2.4 (0.9)
	Median (IQR)	2.3 (1.9 to 2.8)	2.3 (1.9 to 2.7)	2.3 (1.9 to 2.8)	2.3 (1.9 to 2.8)
	Min to Max	0.9 to 7.6	0.9 to 10.9	0.9 to 9.1	0.9 to 10.9

Table 13 :Event rates during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC

Outcome	Cause	N	Events	Event rate /100 person-years	95% CI
All-cause death		1351	50	3.84	(2.91 to 5.07)
	Cardiovascular death	1351	21	1.61	(1.05 to 2.47)
	Non-Cardiovascular death	1351	20	1.54	(0.99 to 2.38)
	Undetermined cause	1351	9	0.69	(0.36 to 1.33)
Stroke/SE		1351	11	0.85	(0.47 to 1.53)
Major bleed		1351	8	0.62	(0.31 to 1.23)
Acute coronary syndrome		1351	9	0.69	(0.36 to 1.33)
Congestive Heart Failure		1351	35	2.73	(1.96 to 3.80)

Table 14: Cause of death during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC

		CZECH REPUBLIC		
Outcome	Cause	N	Events	%
Cardiovascular causes	missing	21	1	4.76
	Myocardial infarction	21	5	23.81
	Congestive heart failure	21	7	33.33
	Sudden or unwitnessed death	21	4	19.05
	Other	21	4	19.05
Non-cardiovascular causes	Respiratory failure	20	3	15.00
	Infection/sepsis	20	5	25.00
	Malignancy	20	9	45.00
	Other	20	3	15.00

Table 15: Type of stroke during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset :CZECH REPUBLIC

OUTCOME	CZECH REPUBLIC		
	N	Events	%
Stroke(not including systemic embolism)	1351	11	0.81
Primary Ischemic Stroke	1351	9	0.67
Primary intracerebral hemorrhage*	1351	1	0.07
<i>Intracerebral</i>	1351	1	0.07
Undetermined	1351	1	0.07

Table 16 : Mortality rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	18	17.93	0	-	-
1	131	127.04	2	1.57	(0.39 to 6.30)
2	307	298.87	4	1.34	(0.50 to 3.57)
3	346	339.15	7	2.06	(0.98 to 4.33)
4+	544	515.21	36	6.99	(5.04 to 9.69)
Unknown	5	4.29	1	23.29	(3.28 to 165.37)

Table 17 : Stroke/SE rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	18	17.93	0	-	-
1	131	126.98	1	0.79	(0.11 to 5.59)
2	307	297.96	1	0.34	(0.05 to 2.38)
3	346	338.29	1	0.30	(0.04 to 2.10)
4+	544	511.74	8	1.56	(0.78 to 3.13)
Unknown	5	4.29	0	-	-

Table 18 : Major bleeding rate by CHA2DS2-VASc score during the first year of follow-up Cohorts 1 to 4
Full Analysis Dataset : CZECH REPUBLIC

CHA2DS2-VASc	N	Person-Years	Events	Event rate /100 person-years	95% CI
0	18	17.93	0	-	-
1	131	127.04	0	-	-
2	307	297.91	1	0.34	(0.05 to 2.38)
3	346	338.23	1	0.30	(0.04 to 2.10)
4+	544	512.64	6	1.17	(0.53 to 2.61)
Unknown	5	4.29	0	-	-